Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Aardvark Adventures -- Ignore unavailable to you. Want to Upgrade?

To: ~digs who wrote (4057)	4/17/2008 8:07:07 PM
From: ~digs	Respond to of 7944

[NASDAQ:CYAN] CYANOTECH CORPORATION > 1.74 Wednesday March 26, 8:30 am ET Cyanotech Focuses Natural Astaxanthin Production on BioAstin(R) for Human Market, Discontinues Production of NatuRose(R) for Animal Feed Market in Strategic Move biz.yahoo.com “Our strategy has evolved to exclusively target the human astaxanthin market where we have a cost advantage. Cyanotech has the largest production capacity of natural astaxanthin in the industry and largest sales of all producers selling astaxanthin into the human nutrition market,” Dr. Cysewski concluded. “We see this important decision as our BioAstin customers' insurance that we will continue to be the most reliable supplier in the industry as natural astaxanthin becomes a more widely used human nutraceutical supplement.”